Trial
NCT01308203
Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease
Phase IVTERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Daniel A. Siniawski
Collaborators
Merck Sharp & Dohme LLC
Condition
Coronary Artery Disease
Intervention
Extended release niacin/laropiprant
Why stopped
Merck has decided to discontinue all studies with extended-release niacin/laropiprant.because the HPS2-THRIVE did not meet its primary endpoint
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-09-21